Boykin v. Genzyme Therapeutic Products

CourtDistrict Court, D. Massachusetts
DecidedJuly 12, 2023
Docket1:21-cv-10115
StatusUnknown

This text of Boykin v. Genzyme Therapeutic Products (Boykin v. Genzyme Therapeutic Products) is published on Counsel Stack Legal Research, covering District Court, D. Massachusetts primary law. Counsel Stack provides free access to over 12 million legal documents including statutes, case law, regulations, and constitutions.

Bluebook
Boykin v. Genzyme Therapeutic Products, (D. Mass. 2023).

Opinion

UNITED STATES DISTRICT COURT DISTRICT OF MASSACHUSETTS

CIVIL ACTION NO. 21-10115-RGS

CHARLES BOYKIN

v.

GENZYME THERAPEUTIC PRODUCTS LP and PAUL BEAUSOLEIL

MEMORANDUM AND ORDER ON DEFENDANTS’ MOTION FOR SUMMARY JUDGMENT

July 12, 2023

STEARNS, D.J. Charles Boykin brings this civil rights action against his former employer, Genzyme Therapeutic Products LP, and his former manager’s superior, Paul Beausoleil, asserting violations of the Civil Rights Act of 1866, 42 U.S.C. § 1981 (Counts I and II); Title VII of the Civil Rights Act of 1964, 42 U.S.C. §§ 2000e et seq. (Count III); and the employment discrimination provisions of Massachusetts law, Mass. Gen. Laws ch. 151B, § 4 (Counts IV and V). Specifically, he alleges that defendants unlawfully discriminated against him on the basis of race and/or retaliated against him for engaging in protected conduct when he received a poor performance review in March of 2018. Defendants move for summary judgment on all claims. For the following reasons, the court will allow the motion. BACKGROUND The essential facts, viewed in the light most favorable to Boykin as the

non-moving party, are as follows.1 Genzyme first hired Boykin in 2013. Although Boykin began as a manufacturing supervisor, at some point prior to 2017, Genzyme promoted him to the position of Senior Site Planning Analyst. As Senior Site Planning Analyst, Boykin managed the cycle count

process2 for Genzyme’s Allston facility and investigated and documented deviations from the company’s standard manufacturing processes at that facility. His manager was Michael Haepers, and Haepers’s superior was

Beausoleil. At some point in 2017, issues began to arise about Boykin’s job performance. First, early in the year, both Genzyme’s Director of Quality and

1 Defendants move to strike Boykin’s Statement of Material Facts (SOF). Having reviewed the parties’ arguments and the relevant submissions, the court will allow the motion to the extent that any fact in Boykin’s SOF is inconsistent with the facts set forth in defendants’ statement (which are deemed admitted given Boykin’s failure to dispute the relevant paragraphs in his statement, see L.R. 56.1; see also Plourde v. Sorin Grp. USA, Inc., 517 F. Supp. 3d 76, 81 (D. Mass. 2021)). The court will, however, deny the motion as to the portions of plaintiff’s SOF that do not conflict with defendants’ statement for the simple reason that, even if considered, nothing in these sections substantively affects the court’s ruling on the merits. See Terry v. SimplexGrinnell LP, 2013 WL 1332240, at *1 (D. Mass. Mar. 28, 2013).

2 Cycle counting is used to state inventory for financial reporting purposes. Beausoleil expressed concerns about the pace at which Boykin was resolving deviation investigations. Beausoleil, for example, sent the following email to

Boykin and others in May of 2017: We now have 2 minor deviations that are past due. This is unacceptable and a key performance indicator for the site and our team. I will setup a deviation meeting to understand why it’s very common for our deviations to go past due this year and get the status of all our deviations.

Ex. A to Beausoleil Aff. [Dkt # 31-1]. Presumably in response to these concerns, Haepers spoke with Boykin about the need to complete deviation investigations more quickly several times throughout 2017. Second, in the fall of that year, Genzyme’s cycle count process failed an outside audit by Pricewaterhouse Coopers. Sebastien Bernhard, the Head of Finance for the Allston facility, criticized Boykin for the failed audit in front of his peers (all of whom were white). Boykin reported Bernhard to HR for alleged racial discrimination, and Bernhard later apologized for his treatment of Boykin. In the winter of 2017, Beausoleil allegedly told another employee that “we finally have a job he [Boykin] can handle” as Boykin was mopping up ice

melt in the facility. Pl.’s SOF [Dkt # 36] ¶ 32. Boykin and the other employee interpreted the comment as a racial remark, invoking historical stereotypes. On December 5, 2017, as the time for year-end reviews approached, Haepers emailed Beausoleil a proposed rating of 3 on Genzyme’s 9-block

performance matrix. Haepers explained that, although Boykin had a “positive attitude,” he could “lose focus at times, especially as the process owner for cycle counting,” and “needs [to] focus on his basic tasks (cycling counting and deviation management).” Ex. B to Beausoleil Aff. [Dkt # 31-2].

Two hours later, Beausoleil instructed Haepers to enter the proposed rating into the system, but not to share it with Boykin for the time being. Months later, on March 20, 2018, Haepers informed Boykin of the 3

rating. Haepers allegedly explained that he had personally wanted to rate Boykin as a 5 but had been overruled by Beausoleil, who thought Boykin was “making too much money.”3 Pl.’s SOF ¶ 34. When Boykin asked if he would receive an Individual Improvement Plan (IIP) because of the rating, Haepers

said that he would. A few days later, before any IIP issued, Boykin requested and received a medical leave of absence. He never returned to work. DISCUSSION Summary judgment is appropriate when, based upon the pleadings,

affidavits, and depositions, “there is no genuine dispute as to any material

3 A 5 rating would have rendered him eligible for a bonus and salary increase, whereas a 3 rating did not. fact and the movant is entitled to judgment as a matter of law.” Fed. R. Civ. P. 56(a). “To succeed, the moving party must show that there is an absence

of evidence to support the nonmoving party’s position.” Rogers v. Fair, 902 F.2d 140, 143 (1st Cir. 1990). “‘[T]he mere existence of a scintilla of evidence’ is insufficient to defeat a properly supported motion for summary judgment.” Torres v. E.I. Dupont De Nemours & Co., 219 F.3d 13, 18 (1st

Cir. 2000), quoting Anderson v. Liberty Lobby, Inc., 477 U.S. 242, 252 (1986). The court assesses the validity of Boykin’s claims using the burden-

shifting paradigm set forth in McDonnell Douglas Corp. v. Green, 411 U.S. 792 (1973).4 See Prescott v. Higgins, 538 F.3d 32, 40 (1st Cir. 2008). Under this paradigm, a plaintiff bears the initial burden “to show . . . a prima facie case of discrimination.” Blare v. Husky Injection Molding Sys. Bos., Inc.,

419 Mass. 437, 441 (1995). If the plaintiff makes the requisite showing, the burden shifts to the employer to “establish a legitimate, nondiscriminatory justification for the adverse employment action.” Ray v. Ropes & Gray LLP, 799 F.3d 99, 113 (1st Cir. 2015). If the defendant proffers a legitimate,

4 Because the federal and state standards do not differ in any respect relevant to the court’s decision, and because the parties themselves do not distinguish between the two, the court will address the state and federal claims together. See Villanueva v.

Free access — add to your briefcase to read the full text and ask questions with AI

Related

McDonnell Douglas Corp. v. Green
411 U.S. 792 (Supreme Court, 1973)
Anderson v. Liberty Lobby, Inc.
477 U.S. 242 (Supreme Court, 1986)
Torres v. E.I. DuPont De Nemours & Co.
219 F.3d 13 (First Circuit, 2000)
Prescott v. Higgins
538 F.3d 32 (First Circuit, 2008)
Ralph Rogers v. Michael Fair
902 F.2d 140 (First Circuit, 1990)
Tino Villanueva v. Wellesley College
930 F.2d 124 (First Circuit, 1991)
Samuel Mesnick v. General Electric Company
950 F.2d 816 (First Circuit, 1991)
Castro-Medina v. Procter & Gamble Commercial Co.
565 F. Supp. 2d 343 (D. Puerto Rico, 2008)
Wheelock College v. Massachusetts Commission Against Discrimination
355 N.E.2d 309 (Massachusetts Supreme Judicial Court, 1976)
Ray, III v. Ropes & Gray LLP
799 F.3d 99 (First Circuit, 2015)
Bulwer v. Mount Auburn Hospital
46 N.E.3d 24 (Massachusetts Supreme Judicial Court, 2016)
Blare v. Husky Injection Molding Systems Boston, Inc.
646 N.E.2d 111 (Massachusetts Supreme Judicial Court, 1995)
Mole v. University of Massachusetts
814 N.E.2d 329 (Massachusetts Supreme Judicial Court, 2004)

Cite This Page — Counsel Stack

Bluebook (online)
Boykin v. Genzyme Therapeutic Products, Counsel Stack Legal Research, https://law.counselstack.com/opinion/boykin-v-genzyme-therapeutic-products-mad-2023.